These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 11956105)

  • 61. The Ret receptor protein tyrosine kinase associates with the SH2-containing adapter protein Grb10.
    Pandey A; Duan H; Di Fiore PP; Dixit VM
    J Biol Chem; 1995 Sep; 270(37):21461-3. PubMed ID: 7665556
    [TBL] [Abstract][Full Text] [Related]  

  • 62. RET alternate splicing influences the interaction of activated RET with the SH2 and PTB domains of Shc, and the SH2 domain of Grb2.
    Lorenzo MJ; Gish GD; Houghton C; Stonehouse TJ; Pawson T; Ponder BA; Smith DP
    Oncogene; 1997 Feb; 14(7):763-71. PubMed ID: 9047383
    [TBL] [Abstract][Full Text] [Related]  

  • 63. A RING finger motif regulates transforming activity of the rfp/ret fusion gene.
    Hasegawa N; Iwashita T; Asai N; Murakami H; Iwata Y; Isomura T; Goto H; Hayakawa T; Takahashi M
    Biochem Biophys Res Commun; 1996 Aug; 225(2):627-31. PubMed ID: 8753810
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Inhibition of Ret oncogene activity by the protein tyrosine phosphatase SHP1.
    Hennige AM; Lammers R; Höppner W; Arlt D; Strack V; Teichmann R; Machicao F; Ullrich A; Häring HU; Kellerer M
    Endocrinology; 2001 Oct; 142(10):4441-7. PubMed ID: 11564708
    [TBL] [Abstract][Full Text] [Related]  

  • 65. The Glu632-Leu633 deletion in cysteine rich domain of Ret induces constitutive dimerization and alters the processing of the receptor protein.
    Bongarzone I; Vigano E; Alberti L; Mondellini P; Uggeri M; Pasini B; Borrello MG; Pierotti MA
    Oncogene; 1999 Aug; 18(34):4833-8. PubMed ID: 10490816
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Absence of MEN2A- or 2B-type RET mutations in primary neuroblastoma tumour tissue.
    Peaston AE; Camacho ML; Norris MD; Haber M; Marsh DJ; Robinson BG; Hyland VJ; Marshall GM
    Mol Cell Probes; 1998 Aug; 12(4):239-42. PubMed ID: 9727201
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Development of medullary thyroid carcinoma in transgenic mice expressing the RET protooncogene altered by a multiple endocrine neoplasia type 2A mutation.
    Michiels FM; Chappuis S; Caillou B; Pasini A; Talbot M; Monier R; Lenoir GM; Feunteun J; Billaud M
    Proc Natl Acad Sci U S A; 1997 Apr; 94(7):3330-5. PubMed ID: 9096393
    [TBL] [Abstract][Full Text] [Related]  

  • 68. [From gene to disease; from the RET gene to multiple endocrine neoplasia types 2A and 2B, sporadic and familial medullary thyroid carcinoma, Hirschsprung disease and papillary thyroid carcinoma].
    Hofstra RM; van der Luijt RB; Lips CJ
    Ned Tijdschr Geneeskd; 2001 Nov; 145(46):2217-21. PubMed ID: 11757244
    [TBL] [Abstract][Full Text] [Related]  

  • 69. The soluble ectodomain of RetC634Y inhibits both the wild-type and the constitutively active Ret.
    Cerchia L; Libri D; Carlomagno MS; de Franciscis V
    Biochem J; 2003 Jun; 372(Pt 3):897-903. PubMed ID: 12630912
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Tyrosine 981, a novel ret autophosphorylation site, binds c-Src to mediate neuronal survival.
    Encinas M; Crowder RJ; Milbrandt J; Johnson EM
    J Biol Chem; 2004 Apr; 279(18):18262-9. PubMed ID: 14766744
    [TBL] [Abstract][Full Text] [Related]  

  • 71. The Y606C RET mutation causes a receptor gain of function.
    Ercolino T; Lombardi A; Becherini L; Piscitelli E; Cantini G; Gaglianò MS; Serio M; Luconi M; Mannelli M
    Clin Endocrinol (Oxf); 2008 Aug; 69(2):253-8. PubMed ID: 18248647
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Replacing two conserved tyrosines of the EphB2 receptor with glutamic acid prevents binding of SH2 domains without abrogating kinase activity and biological responses.
    Zisch AH; Pazzagli C; Freeman AL; Schneller M; Hadman M; Smith JW; Ruoslahti E; Pasquale EB
    Oncogene; 2000 Jan; 19(2):177-87. PubMed ID: 10644995
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Characterization of gene expression induced by RET with MEN2A or MEN2B mutation.
    Watanabe T; Ichihara M; Hashimoto M; Shimono K; Shimoyama Y; Nagasaka T; Murakumo Y; Murakami H; Sugiura H; Iwata H; Ishiguro N; Takahashi M
    Am J Pathol; 2002 Jul; 161(1):249-56. PubMed ID: 12107109
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Tyrosine residues in the C-terminal domain of the insulin-like growth factor-I receptor mediate mitogenic and tumorigenic signals.
    Esposito DL; Blakesley VA; Koval AP; Scrimgeour AG; LeRoith D
    Endocrinology; 1997 Jul; 138(7):2979-88. PubMed ID: 9202243
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Occurrence of pheochromocytoma in a MEN2A family with codon 609 mutation of the RET proto-oncogene.
    Igaz P; Patócs A; Rácz K; Klein I; Váradi A; Esik O
    J Clin Endocrinol Metab; 2002 Jun; 87(6):2994. PubMed ID: 12050290
    [No Abstract]   [Full Text] [Related]  

  • 76. Point mutations in the tyrosine kinase domain release the oncogenic and metastatic potential of the Ron receptor.
    Santoro MM; Penengo L; Minetto M; Orecchia S; Cilli M; Gaudino G
    Oncogene; 1998 Aug; 17(6):741-9. PubMed ID: 9715276
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Roles of induced expression of MAPK phosphatase-2 in tumor development in RET-MEN2A transgenic mice.
    Hasegawa T; Enomoto A; Kato T; Kawai K; Miyamoto R; Jijiwa M; Ichihara M; Ishida M; Asai N; Murakumo Y; Ohara K; Niwa Y; Goto H; Takahashi M
    Oncogene; 2008 Sep; 27(43):5684-95. PubMed ID: 18542059
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Rudolf-Virchow-Preis 1995. The role of RET proto-oncogene mutation analysis in the diagnosis of multiple endocrine neoplasia type 2 (MEN 2) gene carriers and in the discrimination of sporadic and familial medullary thyroid carcinomas and pheochromocytomas.
    Komminoth P
    Verh Dtsch Ges Pathol; 1995; 79():L-LV. PubMed ID: 8600671
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Germ line mutations of the ret proto-oncogene in Japanese patients with multiple endocrine neoplasia type 2A and type 2B.
    Maruyama S; Iwashita T; Imai T; Funahashi H; Ceccherini I; Luo Y; Romeo G; Matsuo S; Matsuyama M; Takahashi M
    Jpn J Cancer Res; 1994 Sep; 85(9):879-82. PubMed ID: 7961113
    [TBL] [Abstract][Full Text] [Related]  

  • 80. The oncogenic activity of RET point mutants for follicular thyroid cells may account for the occurrence of papillary thyroid carcinoma in patients affected by familial medullary thyroid carcinoma.
    Melillo RM; Cirafici AM; De Falco V; Bellantoni M; Chiappetta G; Fusco A; Carlomagno F; Picascia A; Tramontano D; Tallini G; Santoro M
    Am J Pathol; 2004 Aug; 165(2):511-21. PubMed ID: 15277225
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.